Suppr超能文献

基于流穿式的高通量和高序列覆盖度方法开发,用于治疗性 mRNA 的快速及全面测序。

Development of a Flow Through-Based Limited Digestion Approach for High-Throughput and High-Sequence Coverage Mapping of Therapeutic mRNAs.

机构信息

Analytical Chemistry Group, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707, United States.

出版信息

Anal Chem. 2024 Oct 22;96(42):16994-17003. doi: 10.1021/acs.analchem.4c04384. Epub 2024 Oct 11.

Abstract

Messenger RNAs (mRNAs) have rapidly emerged as a pivotal class of biotherapeutics with great promise in the prevention and treatment of various diseases. As with other biotherapeutics, the sequence accuracy and integrity of mRNAs are critical quality attributes (CQAs), influencing the translation efficiency and protein expression fidelity of mRNAs. Due to the generation of short and repetitive oligonucleotides, traditional sequence mapping methods, which utilize in-solution RNase T1 digestion followed by LC-MS/MS analysis, face challenges in achieving high sequence coverage. In this study, we developed a novel flow through (FT)-based strategy to achieve the limited RNase T1 digestion of therapeutic mRNAs, leading to improved mRNA sequence mapping by LC-MS/MS analysis. Compared with the traditional in-solution digestion methods, the FT-based digestion method could consistently generate an increased number of unique oligonucleotides with miscleavages, which significantly boosted the overall sequence coverage (over 93%) of therapeutic mRNAs of varying sizes. Moreover, the automated digestion workflow using the AssayMAP platform offers significant advantages in method reproducibility and throughput. The high throughput and high sequence coverage features of this method could facilitate its wide application in the development of mRNA-based therapeutics.

摘要

信使 RNA(mRNA)迅速成为一类重要的治疗药物,在预防和治疗各种疾病方面具有巨大的潜力。与其他治疗药物一样,mRNA 的序列准确性和完整性是关键质量属性(CQA),影响 mRNA 的翻译效率和蛋白质表达保真度。由于短而重复的寡核苷酸的产生,传统的基于溶液的序列映射方法,利用溶液中的 RNase T1 消化,然后进行 LC-MS/MS 分析,在实现高序列覆盖方面面临挑战。在本研究中,我们开发了一种新颖的基于流通过滤(FT)的策略,以实现治疗性 mRNAs 的有限 RNase T1 消化,从而通过 LC-MS/MS 分析提高 mRNA 序列映射。与传统的溶液消化方法相比,FT 基消化方法可以一致地产生更多具有错误切割的独特寡核苷酸,这显著提高了不同大小的治疗性 mRNAs 的整体序列覆盖率(超过 93%)。此外,使用 AssayMAP 平台的自动消化工作流程在方法重现性和通量方面具有显著优势。该方法的高通量和高序列覆盖特性可促进其在基于 mRNA 的治疗药物开发中的广泛应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4986/11503513/5605ecf7e958/ac4c04384_0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验